4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) appears in 149 institutional 13F filings for the quarter ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| Janus Henderson Group Plc | 31 Mar, 2026 | 10,494,302 | 5,858,427 | 126.37% | $97,736,328.00 |
| Goldman Sachs Group Inc | 31 Mar, 2026 | 8,605,810 | 4,477,394 | 108.45% | $64,543,578.00 |
| RA CAPITAL MANAGEMENT, L.P. | 31 Mar, 2026 | 5,653,211 | 1,090,000 | 23.89% | $42,399,083.00 |
| RA CAPITAL MANAGEMENT, L.P. | 31 Mar, 2026 | 5,049,779 | -603,432 | -10.67% | $47,013,442.00 |
| Janus Henderson Group Plc | 31 Mar, 2026 | 4,635,875 | 2,882,508 | 164.40% | $34,726,165.00 |
| BVF INC/IL | 31 Mar, 2026 | 4,629,289 | 0 | 0.00% | $34,719,668.00 |
| Goldman Sachs Group Inc | 31 Mar, 2026 | 4,205,438 | -4,400,372 | -51.13% | $39,152,628.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 4,145,303 | 80,427 | 1.98% | $38,592,771.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 4,064,876 | 195,746 | 5.06% | $30,486,573.00 |
| Novo Holdings A/S | 31 Mar, 2026 | 3,650,737 | 0 | 0.00% | $33,988,361.00 |
| Novo Holdings A/S | 31 Mar, 2026 | 3,650,737 | 1,650,737 | 82.54% | $27,380,528.00 |
| VANGUARD GROUP INC | 31 Mar, 2026 | 3,093,527 | 518,405 | 20.13% | $23,201,453.00 |
| BVF INC/IL | 31 Mar, 2026 | 2,879,289 | -1,750,000 | -37.80% | $26,806,181.00 |
| State Street Corp | 31 Mar, 2026 | 2,707,875 | 18,995 | 0.71% | $25,210,316.00 |
| State Street Corp | 31 Mar, 2026 | 2,688,880 | 1,785,106 | 197.52% | $20,166,600.00 |
| ARMISTICE CAPITAL, LLC | 31 Mar, 2026 | 2,000,000 | 64,000 | 3.31% | $18,620,000.00 |
| ARMISTICE CAPITAL, LLC | 31 Mar, 2026 | 1,936,000 | 840,000 | 76.64% | $14,520,000.00 |
| Federated Hermes, Inc. | 31 Mar, 2026 | 1,609,482 | 14,650 | 0.92% | $12,071,116.00 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 31 Mar, 2026 | 1,605,156 | 370,000 | 29.96% | $14,944,002.00 |
| Point72 Asset Management, L.P. | 31 Mar, 2026 | 1,539,860 | 1,539,860 | 0.00% | $11,548,950.00 |